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117 character summary: 
In 2009–14, HIV/TB, TB drug resistance & worse outcome significantly increased in Bucharest 





Although the incidence of tuberculosis (TB) is declining in most EU countries, and despite recent 
progress, notification rates in Romania are several times higher than the European mean of 
13.5 per 100,000. It is one of the 18 TB high-priority countries within the WHO European Region 
(1). In 2015, out of the 60,195 TB cases reported by the 30 EU/EEA countries, one-quarter were 
from Romania (2). 
 
The number of injecting drug users (IDUs) in the general Romanian population has increased by 
almost 9% since 2007 (3). Its geographic location ensures that Romania is part of the Balkan 
route of heroin trafficking. Moreover, in the last few years a new “legal drugs” market has 
arisen, with increasing use of psychoactive drugs, known as “ethnobotanicals”. These are 
derived from cathinones and are a mixture of chemical powders such as mephedrone, MDPV 
(Methylenedioxypyrovalerone), 5-MeO-DALT, phenetylamine or benzopyrone. Ethnobotanicals 
have psychoactive effects similar to those produced by amphetamines. These drugs are 
commercialized as “spice – type” smoking drugs or synthetic psychoactive substances that can 
be injected or sniffed (3). They are cheap and therefore affordable for most IDUs. They are also 
highly addictive and require multiple injections (6-10 times/day) - thus the risk of acquiring 
bacterial and viral infections with their use is very high (3-7). 
 
By the end of 2014, there were 12,886 people living with HIV/AIDS (PLWH) in Romania. The 
number of newly diagnosed cases per year has increased progressively, from 445 in 2007 to 
over 900 in 2014 (8). While the majority of HIV/AIDS cases reported during the 1990s arose 
from the cohort of children infected via the parenteral mode in the late 1980s, the HIV 
epidemic in Romania today now follows the general European trend, with an increasing 
incidence in IDUs and men who have sex with men (MSM). In 2007, IDUs accounted for 2% of 
new cases of HIV, by 2014 this had increased to more than 20%, associated with a concomitant 
spread of hepatitis B and C and severe cases of systemic bacterial infections (8-11). In addition, 
in 2014 16% of Romanian IDUs diagnosed with HIV also had pulmonary TB (9).  
 
The “Victor Babes” Clinical Hospital for Infectious Diseases (SVB), Bucharest, is a tertiary referral 
centre which manages a large national case-load of known HIV-infected IDUs. The aims of our 
study were: to determine the prevalence of TB among IDUs newly diagnosed with HIV admitted 
to SVB; to describe their demographic and clinical characteristics according to TB co-infection 







We performed a prospective study of adult IDUs with HIV admitted to SVB between January 
2009 and December 2014. It is standard practice in Romania for people who inject drugs to be 
admitted at the time of HIV diagnosis. HIV testing is mandatory for all new TB diagnoses, and all 
patients with suspected or diagnosed TB are also admitted. Therefore, almost all IDUs 
diagnosed with TB who are HIV positive are managed in our service, plus >90% of those with 
HIV mono-infection. Social, demographic and clinical characteristics were obtained from clinical 
databases from the time of admission until the date of last follow-up of on 31 December 2015. 
 
All patients satisfying study criteria gave informed consent to participate in this work. 
 
Tuberculosis diagnosis and disease classification 
TB diagnosis was classified as definitive (positive mycobacterial cultures, molecular tests, MTB-
PCR and histopathological examination) or presumptive (based on clinical, radiological findings, 
histopathology and response to empirical treatment). Clinical forms of TB were categorized as 
pulmonary TB, extra-pulmonary TB and disseminated TB (in patients with both pulmonary and 
extra-pulmonary involvement). 
 
In line with recommended definitions, a CD4 cell count < 350/mm3 at the time of HIV diagnosis 




Individuals were followed from the date of HIV diagnosis until the time of death or last follow-
up at 31st December 2015. The prevalence of TB co-infection at HIV diagnosis or immediately 
after this was summarized by calendar year, and investigated using a test for trend. 
Demographic and clinical characteristics at the time of HIV diagnosis were compared according 
to TB co-infection status. Comparisons of categorical variables were made using chi-squared 
test or Fisher’s exact test, as appropriate. Comparisons of continuous variables, such as CD4 
count, age and HIV load were made using the Wilcoxon rank sum test. Amongst the subgroup 
with TB, we calculated the short-term mortality as the percentage that died within 3 months of 
diagnosis and the longer-term mortality as the death rate per 1000 person-years from three 
months post-diagnosis onwards, according to the site of TB. Finally, the time to death was 
compared between HIV and TB-co infected IDUs and HIV-infected IDUs without TB using 
standard survival methods of Kaplan-Meier plots, and log rank tests. 
 
Analyses were performed using SPSS version 20 and STATA version SE 14.0. A p value of < 0.05 




Comparison of HIV-infected IDUs with and without TB 
A total of 598 injecting drug users were diagnosed with HIV, with a median follow-up of 30.0 
(IQR 17.8, 42.1) months. 170 (28.5%) were also diagnosed with active TB, of whom 153/170 
(90%) had a simultaneous diagnosis of both HIV and TB. The remaining 17/170 (10%) were 
diagnosed with TB a median of 140 (IQR 100 -284) days after HIV diagnosis. TB prevalence 
among HIV infected IDUs rose dramatically from 2009 to 2013 with a slight decrease in 2014 
(p<0.001) (Figure 1) 
 The majority of IDUs were young, from urban areas and male (Table 1). There were no 
differences according to TB co-infection status with respect to gender, age at HIV diagnosis and 
median duration of injecting drug use. A significantly higher proportion of the HIV/TB co-
infected IDUs were unemployed and of low educational level compared to HIV-infected IDUs 
without TB. A history of multiple sexual partners/unprotected sexual intercourse was 
significantly more common in IDUs without TB. 
 
About one third of the patients, irrespective of TB status, had used drugs for more than 10 
years. Few reported starting drug use within the last 12 months (2.3% [4/170] vs. 3.9% 
[17/428]; p=0.33). The majority of IDUs injected both heroin and psychoactive drugs. However, 
TB co-infected patients were more likely to exclusively use ethnobotanicals, or in combination 
with other smoked drugs; whereas heroin use alone or in combination with other psycho-active 
drugs was more commonly reported in those without TB (Table 1).  
 
HIV infection status and viral hepatitis co-infection 
Blood CD4 cell count at HIV diagnosis was available for 84.6% (506) IDUs: 100% (170/170) with 
and 78.5% (336/428) without TB. HIV load was available in 36.8% (220) IDUs: 33.5% (57) with 
TB and 38.1% (163) without TB.  The median CD4 cell count/mm3 at HIV diagnosis was lower for 
IDUs with TB compared to non-TB IDUs: 75/mm3 vs. 450/mm3 (p<0.0001) (Table 2). In addition, 
a significantly higher percentage of IDUs who developed TB were diagnosed as late-presenters 
(CD4 cell count<350/mm3) compared to the non TB IDUs (p<0.0001). Even so, 26 patients 
(15.2%) developed TB with a blood CD4 >500 cell/mm3. Among those who injected drugs for 
more than 10 years, HIV/TB co-infected IDUs had more severe immunosuppression (median 
CD4 cell counts 51/mm3 vs 478/mm3 in those without TB, p<0.0001). The median HIV load at 
HIV diagnosis was higher for TB co-infected patients (5.6 log10 vs. 4.9 log10, p=0.0002). Almost all 
IDUs (90.0%, 198/220) had a HIV viral load >105 copies/ml (Table 2).  
 
Irrespective of their TB status, most patients were co-infected with HCV (98.3% [588]). IDUs 
without TB were more likely to be HBs Ag positive (Table 2, p=0.004). Overall, antiretroviral 
treatment (ART) was ever initiated in 30.1% (180) patients, with a higher percentage starting in 
the TB co-infected subgroup (p<0.0001). 
 
Clinical characteristics of HIV-infected IDUs with TB  
105 patients had positive mycobacterial cultures, and 15 positive MTB-PCR samples. A total of 
96/170 (56.4%) patients had only positive cultures: 90 from sputum, 3 from cerebro-spinal fluid 
(CSF), 2 from lymph node aspirate and 1 from bronchial aspirate. TB diagnosis was established 
only by MTB-PCR in 6/170 (3.5%) cases, from sputum and bronchial aspirate in 4 cases and CSF 
in 2. There were also 9/170 (5.2%) patients who had both positive cultures and MTB-PCR 
(lymph nodes 4, CSF 3, ascites 1 and pleural fluid 1). In the remaining 65/170 cases (38.2%) the 
diagnosis was presumptive. 
 
The majority of IDUs diagnosed with TB developed pulmonary disease, 103/170 (60.6%), 
approximately a quarter had disseminated disease (49/170; 28.8%) and 10.5% (18) had extra-
pulmonary disease. Among patients with extra-pulmonary TB, 10 were diagnosed with TB 
meningoencephalitis, 6 with intestinal TB, 1 with osteo-articular TB and 1 hepato-splenic TB. 
 
All 105 TB positive cultures underwent drug susceptibility testing. Overall, 28 (26.7%) had 
clinically relevant drug resistance. Resistance to either INH or RMP was present in 10 (9.5%), 7 
(6.6%) were resistant to both INH and RMP (ie MDR) and 11 (10.4%) isolates were extensively 
drug resistant (XDR) - of which 10 were identified in 2014.   
 
Time to death according to presence of TB 
 A total of 72 individuals died (12%; 72/598), comprising 23.5% (40/170) of those with TB 
compared to 7.4% (32/428) of those without, p<0.0001 (Figure 2A). The percentage of people 
still alive at one year was 93.5% (95% CI 90.7%, 95.4%; Kaplan-Meier estimate) for those with 
HIV only, and 80.6% (73.8%, 85.8%) in IDUs co-infected with both TB and HIV. 
 
Time to death according to site of TB disease and presence of TB drug resistance 
When considering the sub-group co-infected with both HIV and TB, the incidence of early 
(within 3 months of diagnosis) and late (from 3 months onwards) mortality was higher in IDUs 
with extra-pulmonary TB, and those with XDR strains (Table 3). These results were corroborated 
in Kaplan-Meier plots demonstrating different survival times according to the site of TB disease 




In 2015, there were 15,195 cases of TB in Romania, giving a notification rate of 76.5 per 
100.000 inhabitants (2). TB is one of the commonest opportunistic infections associated with 
HIV infection (8). Among TB cases nationally the HIV incidence per 100 people has risen from 
0.11 in 1990 to 0.93 in 2014, with a peak of 1.37 in 2011 (8). In our prospective study we report 
an approximately two-fold increase in the prevalence of HIV/TB co-infection in IDUs presenting 
at a Romanian tertiary care centre between 2009 and 2014. The majority of patients were 
diagnosed with both HIV and TB simultaneously, and had advanced HIV infection.  
 
It has been previously shown that PLWH with lower CD4 counts are more likely to develop TB 
when compared to people with better immune status at HIV diagnosis (14-17). Similar to data 
reported annually from ECDC (2), we found pulmonary TB to be the most frequent clinical form 
of disease. However, extra pulmonary TB was associated with more severe immunosuppression 
and a higher mortality – likely as a result of over half of the cases presenting with TB meningitis. 
 
The mortality rate in our study was higher for IDUs diagnosed with TB. This is in line with other 
European reports which also found a greater risk of death in patients with TB – in particular 
during the first year following HIV diagnosis (18). Amongst IDUs with TB, the mortality rate was 
greatest in those with extra pulmonary disease, and people with XDR TB. 
 
Although ART increases survival in HIV/TB co-infected patients (19), delay in its initiation, itself 
often due to late diagnosis, is associated with worse outcome (18). In our centre, antiretroviral 
treatment was started more often in IDUs with TB - usually due to their presentation with 
severe immunosuppression. The limited information regarding adherence to ART in our patient 
population makes it difficult to comment on its impact - though it is perhaps relevant that 
survival was significantly worse in patients with TB co-infection over the first two years from 
HIV diagnosis (Figure 2A).    
 
We found the profile of a HIV/TB co-infected IDU to be an unemployed urban male, with a low 
level of education, who was using mainly ethnobotanical drugs. Smoked drugs were more often 
used in combination with injectables by TB patients. This is in agreement with literature 
highlighting the association between inhaled crack cocaine and smear-positive TB possibly due 
to respiratory damage (20).  
 
Although the percentage of TB in IDUs was higher in patients with a history of imprisonment, 
this was not statistically significant. Other risk factors such as tattoos or piercings commonly 
reported to be associated with TB (14, 15, 21, 22), were not identified in our study.  
 
The frequent use of injectable drugs, in particular ethnobotanicals which involve multiple 
administrations per day, often using unsterile injecting equipment, has been associated with a 
very high frequency of viral hepatitis (3-7, 11). Inevitably, almost all IDUs from our study were 
HCV antibody positive; though Hepatitis B surface antigen positivity was more common in IDUs 
without TB. This may relate to a greater proportion of these patients reporting multiple 
partners or unprotected sexual intercourse. The data suggesting that TB IDUs reported less 
sexual partners than non-TB IDUs might be explained by the former group being less social, and 
hence possibly less likely or able to seek healthcare and/or be advised to do so by others when 
unwell. This would be consistent with the worse immunological status and higher HIV load 
found in the TB IDUs at the time of their HIV diagnosis.  
 
Studies performed in Eastern Europe have highlighted the possible association between 
injecting drug use, HIV and MDR-TB (23). Over the last decade, drug-resistant TB has become a 
particular challenge for TB management. This has had a major impact on survival in IDUs (24). 
The number of MDR and XDR TB cases in our study increased annually, spiking in the last year 
of this report. It is a particular concern as patients with drug resistance are harder to treat, and 
likely therefore to be infectious to others for longer. The dissemination of resistant TB strains 
among vulnerable groups, as well as the general population, represents a challenge for health 
care systems that are already struggling to manage patients with complex psycho-social issues. 
The higher costs of treatment of such patients do not necessarily translate into better 
outcomes. Despite the greater availability of ART in Eastern Europe countries over the last 
decade, mortality among HIV infected patients with drug-resistant TB has been reported to 
approach 30% (25, 26). 
 
Limitations 
Despite our hospital being a large, national centre providing care to HIV-infected IDUs from all 
over Romania, this is a single site study performed over a relatively short period of time. 
However, we are unaware of similar data on HIV and TB in Romanian IDUs. 
 
The diagnosis of TB was definitive (confirmed by positive culture) in over half of our patients. 
This is in line with that reported by ECDC in 2013 for all TB cases in both Europe (almost 60%) 
and Romania (65.2%) (2). A limitation of our study is that blood CD4 cell counts and HIV load 
were not available for all study subjects at HIV diagnosis. Also, the recording of antiretroviral 
use was incomplete – making it difficult to compare our data with that from other countries; 
though we are aware that this is a common challenge in Eastern Europe (25, 26). Finally, we 




TB prevalence in HIV infected Romanian IDUs has increased over the last decade and significant 
TB drug resistance has emerged as a particular issue. The management of IDUs with HIV is 
difficult due to their severe addiction and/or neuro-psychiatric disorders plus possible poor 
adherence to ART. Under these circumstances we believe that strengthening HIV transmission 
prevention methods, particularly in identified risk groups, whilst addressing the surge in TB is 
vital. A multidisciplinary approach, including national policies for routine HIV and hepatitis 
testing for IDUs, improvement of harm-reduction programs (needle/syringe exchange programs 
and opioid substitution treatment services), linkage to care and treatment for HIV, viral 
hepatitis and TB are needed to be implemented urgently if we are to improve outcomes in this 
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Figure 1. Number and percentage of HIV-infected injecting drug users diagnosed with TB January 2009 





























































Table 1. Socio-demographic characteristics, lifestyle factors and injecting drug behavior in HIV infected 








IDUs with TB 
n=170  
 




Socio-demographic variables  
Male                                                n (%) 504 (84.2) 144 (84.7) 360 (84.1) 0.90 
Urban areas                                   n (%) 543 (90.8) 153 (90.0) 390 (91.1) 0.64 
Median age                        (years, IQR) 29 (25 - 33) 30 (25 - 34) 29 (25 - 33) 0.07 
Unemployed                                  n (%) 373 (62.4) 138 (81.1) 235 (54.9) <0.0001 
Fewer than 8 years’ education   n (%) 442 (73.9) 150 (88.2) 292 (68.2) <0.0001 
Median age at drug use initiation                   
                                             (years, IQR) 
19 (16 - 24) 20 (16 - 26) 19 (16 - 23) 0.02 
Median time on drugs  
                                         (months, IQR) 
108 (48-156) 102 (48 - 144) 108 (48 - 156) 0.23 
Type of drug                                 n (%)  
Heroin alone                                      107 (17.8) 20 (11.7) 87 (20.3) <0.0001 
Ethnobotanicals alone                       88 (14.7) 40 (23.5) 48 (11.2)  
Heroin & ethnobotanicals    331 (55.3) 95 (55.8) 236 (55.1)  
Heroin, ethnobotanicals and other 
injecting psycho-active drugs           
47 (7.8) 3 (1.8) 44 (10.2)  
Heroin, ethnobotanicals and non-
injecting drugs 
25 (4.1) 12 (7.1) 13 (3.0)  
Risk factors                                  
Smoking                                         n (%) 355 (59.3) 104 (61.1) 251 (58.6) 0.58 
Alcohol consumption                   n (%) 85 (14.2) 26 (15.2) 59 (13.7) 0.69 
Imprisonment                               n (%) 139 (23.2) 48 (28.2) 91 (21.2) 0.06 
Tattoos                                           n (%) 450 (75.2) 123 (72.3) 327 (76.4) 0.35 
Piercing                                          n (%) 38 (6.3) 5 (2.9) 33 (7.7) 0.03 
Surgery/blood transfusion history 
                                                         n (%) 
137 (22.9) 43 (25.2) 94 (21.9) 0.38 
Multiple sexual partners *and 
unprotected sexual intercourse  
                                                         n (%) 
241 (40.3) 38 (22.3) 203 (47.4) <0.0001 
Needle sharing                              n (%) 59 (9.8) 12 (7.0) 47 (10.9) 0.17 
* more than 5 partners 
IDU=injecting drug user; IQR=inter-quartile range; TB=tuberculosis. 
P-values calculated using chi-squared test or Fisher’s Exact test for categorical variables and Wilcoxon 
rank sum test for continuous variables. 
  





IDUs with TB 
n=170  
IDUs without TB 
n=428  
p value 
CD4 cell count (cells/mm3) 























Advanced HIV disease** 









Median HIV viral load (log10 
copies/mL)       
N with measurement (%) 

















Number of IDUs who initiated ART *      








Anti HCV antibody positive                          








HBs Antigen positive                                      








*At any point over follow-up 
** Of those with an available CD4 measurement 
ART=Antiretroviral therapy; HBs=Hepatitis B surface; HCV=hepatitis C virus; IDU=injecting drug user; 
IQR=inter-quartile range; TB=tuberculosis. 
 P-values calculated using chi-squared test or Fisher’s Exact test for categorical variables and Wilcoxon 
rank sum test for continuous variables. 
 
  
 Table 3. Blood CD4 cell count at diagnosis and mortality among HIV/TB co-infected patients, stratified 
by clinical features of TB and resistance profile of identified Mycobacterium tuberculosis strains 
 




Ever died Early death* 
 
Late death** 
 N (%) Median 
(IQR) 






Site of disease (n=170 IDUs diagnosed with TB) 




18 (17.5) 8 (7.8) 3.4, 14.7 10/2766.2 3.6 1.7, 6.7 
Extra pulmonary 
TB      
18 (10.5) 25  
(12, 64) 
9 (50.0) 7 (38.9) 17.2, 64.3 2/338.5 5.9 0.7, 21.3 
Disseminated TB          49 (28.8) 30  
(13, 124) 
13 (26.5) 8 (16.3) 7.3, 29.7 5/966.9 5.2 1.7, 12.1 
Resistance profile (n=105 positive cultures) 
Fully susceptible 77 (73.3) 50  
(15, 248) 
16 (20.8) 8 (10.4) 4.6, 19.4 8/1709.2 4.7 2.0, 9.2 
Resistant to INH or 
RMP 
10 (9.5) 28  
(19, 58) 
4 (40.0) 3 (30.0) 6.7, 65.2 1/204.5 4.9 0.1, 27.3 
MDR 7 (6.6) 105  
(21, 392) 
1 (14.2) 0 (0.0) 0.0, 41.0 1/193.2 5.2 0.1, 28.8 
XDR 11 (10.4) 42  
(12, 84) 
8 (72.2) 4 (36.3) 10.9, 69.2 4/100.0 40.0 10.9, 102.4 
* Within 3 months of TB diagnosis 
** From 3 months after TB diagnosis onwards 
*** Per 1000 person-years 
 
CI=Confidence interval; IDU=injecting drug user; INH=Isoniazid; IQR=inter-quartile range; MDR=Multi-
Drug Resistance; RMP=Rifampicin; TB=tuberculosis; XDR=Extensive Drug Resistance. 
 
  
Figure 2. Kaplan-Meier plots survival estimates depending on TB co-infection (2A), clinical form of TB 
(2B) and resistance profile (2C) 
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